How many drugs treat Bacterial urinary infection?

Drug Landscape tracks 10 marketed treatments for Bacterial urinary infection (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/bacterial-urinary-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Bacterial urinary infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bacterial urinary infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Bacterial urinary infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Fetroja	CEFIDEROCOL	Shionogi	Cephalosporin Antibacterial		2019-01-01
Avycaz	AVIBACTAM	Cerexa Inc	beta Lactamase Inhibitor [EPC]		2015-01-01
Zymar	GATIFLOXACIN	Allergan		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Cystadane	BETAINE	Recordati	Methylating Agent [EPC]		1996-01-01
Maxipime	Cefepime Hydrochloride	Baxter	Cephalosporin	Bacterial cell wall peptidoglycan	1996-01-01
Maxipime	CEFEPIME	Baxter	Cephalosporin Antibacterial		1996-01-01
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 14 drugs in Bacterial urinary infection
GSK · 4 drugs in Bacterial urinary infection
Pfizer · 3 drugs in Bacterial urinary infection
Bristol-Myers Squibb · 3 drugs in Bacterial urinary infection
Baxter · 2 drugs in Bacterial urinary infection
Pai Holdings Pharm · 2 drugs in Bacterial urinary infection
Shionogi · 2 drugs in Bacterial urinary infection
Bulovka Hospital · 1 drug in Bacterial urinary infection
Assistance Publique - Hôpitaux de Paris · 1 drug in Bacterial urinary infection
Dr Reddys Labs Sa · 1 drug in Bacterial urinary infection
Dr Reddys Labs Inc · 1 drug in Bacterial urinary infection
Cerexa Inc · 1 drug in Bacterial urinary infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Bacterial urinary infection:

Cite this brief

Drug Landscape (2026). Bacterial urinary infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/bacterial-urinary-infection. Accessed 2026-06-10.

Bacterial urinary infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing